Literature DB >> 20397957

From HIV to tuberculosis and back again: a tale of activism in 2 pandemics.

Mark Harrington1.   

Abstract

Tuberculosis (TB) and human immunodeficiency virus (HIV) infections are the deadliest chronic infections globally. Although each is deadly alone, they are deadlier together, with TB causing one-quarter of AIDS-related deaths and HIV infecting at least 15% of patients with TB worldwide. Historically, the 2 diseases were treated through specific, vertical programs. Strong activism and massive scientific investment have boosted the global response to AIDS, whereas TB has suffered from weak advocacy and anemic research funding. However, since 2004, there has been increasing collaboration and convergence between programs to control the 2 diseases, driven by the recognition that program cooperation leads to synergistic gains in strengthening responses to the 2 diseases and to health systems in general. Progress to date is incomplete, however, and countries must rededicate themselves to scaling up prevention and treatment programs for TB and HIV infection toward universal access, while pursuing accelerated research efforts to develop effective vaccines, better treatments, and cures for both diseases.

Entities:  

Mesh:

Year:  2010        PMID: 20397957     DOI: 10.1086/651500

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Pre-steady-state kinetics of interaction of wild-type and multiple drug-resistant HIV protease with first and second generation inhibitory drugs.

Authors:  N A Kuznetsov; A V Kozyr; M A Dronina; I V Smirnov; E N Kaliberda; A G Mikhailova; L D Rumsh; O S Fedorova; A G Gabibov; A V Kolesnikov
Journal:  Dokl Biochem Biophys       Date:  2011-11-19       Impact factor: 0.788

2.  Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization.

Authors:  Haileyesus Getahun; Mario Raviglione
Journal:  Bull World Health Organ       Date:  2011-08-01       Impact factor: 9.408

Review 3.  The non-human primate model of tuberculosis.

Authors:  D Kaushal; S Mehra; P J Didier; A A Lackner
Journal:  J Med Primatol       Date:  2012-03-20       Impact factor: 0.667

4.  Spectrum of AIDS Defining Opportunistic Infections in a Series of 77 Hospitalised HIV-infected Omani Patients.

Authors:  Abdullah A Balkhair; Zakariya K Al-Muharrmi; Shyam Ganguly; Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

5.  A novel tuberculosis DNA vaccine in an HIV-1 p24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1.

Authors:  Xiaoman Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

6.  Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus.

Authors:  Smriti Mehra; Nadia A Golden; Noton K Dutta; Cecily C Midkiff; X Alvarez; Lara A Doyle; Majdouline Asher; Kasi Russell-Lodrigue; Chris Monjure; Chad J Roy; James L Blanchard; Peter J Didier; Ronald S Veazey; Andrew A Lackner; Deepak Kaushal
Journal:  J Med Primatol       Date:  2011-08       Impact factor: 0.667

Review 7.  Experimental primates and non-human primate (NHP) models of human diseases in China: current status and progress.

Authors:  Xiao-Liang Zhang; Wei Pang; Xin-Tian Hu; Jia-Li Li; Yong-Gang Yao; Yong-Tang Zheng
Journal:  Dongwuxue Yanjiu       Date:  2014-11-18

8.  HIV/TB co-infection in mainland China: a meta-analysis.

Authors:  Lei Gao; Feng Zhou; Xiangwei Li; Qi Jin
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

Review 9.  Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms.

Authors:  Mohammad S Islam; Jacob P Richards; Anil K Ojha
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091

Review 10.  Global tuberculosis control: lessons learnt and future prospects.

Authors:  Christian Lienhardt; Philippe Glaziou; Mukund Uplekar; Knut Lönnroth; Haileyesus Getahun; Mario Raviglione
Journal:  Nat Rev Microbiol       Date:  2012-05-14       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.